Strong Q4 2024 Financial Performance and 2025 Outlook
February 6, 2025 - 17:33
In the fourth quarter of 2024, the company reported a remarkable 45% increase in revenue, reaching $13.53 billion. This surge was primarily fueled by significant volume growth from its flagship products, Mounjaro and Zepbound. The performance in this quarter showcases the company's robust market presence and the effectiveness of its growth strategies.
Additionally, non-incretin revenue experienced a solid 20% increase compared to the same period in 2023, reflecting the company's diverse portfolio and successful expansion into new therapeutic areas. The strong financial results indicate not only the popularity of its current offerings but also the potential for future growth.
Looking ahead, the company has provided guidance for 2025, emphasizing its commitment to innovation and market leadership. With a focus on enhancing product accessibility and exploring new opportunities, the company is well-positioned to sustain its momentum and deliver continued value to stakeholders in the coming year.
MORE NEWS
March 19, 2026 - 04:45
Climate Finance Has Failed Africa Twice Over. Here’s How To Fix It.The global system designed to fund climate action is failing Africa profoundly and on two critical fronts. Not only is the continent receiving a minuscule fraction of the necessary financing to...
March 18, 2026 - 21:44
Fed meeting live updates: Federal Reserve holds rates steady, forecasts 1 rate cut in 2026In a widely anticipated move, the Federal Reserve concluded its June policy meeting by holding its benchmark interest rate steady at a 23-year high. The decision underscores the central bank`s...
March 18, 2026 - 00:00
New Rules Reshape the Home Equity Line of Credit LandscapeThe familiar flexibility of the Home Equity Line of Credit (HELOC) is undergoing a significant shift. Driven largely by nonbank lenders entering the market, new requirements are emerging that could...
March 17, 2026 - 04:47
Close Brothers plunges as short seller claims it understated car finance risksShares in Close Brothers Group suffered a dramatic fall, dropping as much as 14% in a single trading session. The sharp decline was triggered by a report from short-selling firm Viceroy Research,...